title: [TUT-7 early phase II clinical study for various solid tumors and hematologic malignancies].
abstract: An early Phase II study with TUT-7 (menogaril), a new anthracycline antitumor antibiotic, was conducted in patients with various malignant tumors at 81 departments of 65 institutions nationwide. One course of TUT-7 treatment consisted of seven (7) or fourteen (14) consecutive days of administration at 75 or 100 mg/body/day with two-week drug withdrawal; at least two courses of treatment were given in principle. Among the 165 patients registered, 145 patients were eligible and 128 patients were evaluable for antitumor efficacy. In 11 patients with malignant lymphoma, one (1) had CR and five (5) had PR (54.5%); in three (3) patients with prostate cancer, one (1) had PR (33.3%); and in 12 patients with uterine cervical cancer, two (2) had PR (16.7%). Adverse drug reactions frequently observed were digestive organ disorders (anorexia and nausea/vomiting) and malaise. The abnormality in laboratory tests observed frequently was myelosuppression (leukopenia and neutropenia).
authors.affiliation: Research Institute for Microbial Diseases, Osaka University.
authors.forename: T
authors.initials: T
authors.lastname: Taguchi
authors.forename: A
authors.initials: A
authors.lastname: Wakui
authors.forename: H
authors.initials: H
authors.lastname: Niitani
authors.forename: H
authors.initials: H
authors.lastname: Furue
authors.forename: H
authors.initials: H
authors.lastname: Majima
authors.forename: K
authors.initials: K
authors.lastname: Ota
authors.forename: H
authors.initials: H
authors.lastname: Ariyoshi
authors.forename: T
authors.initials: T
authors.lastname: Hattori
authors.forename: K
authors.initials: K
authors.lastname: Sugimachi
authors.forename: S
authors.initials: S
authors.lastname: Tsukagoshi
mesh_terms: D000328:Adult; D000855:Anorexia / Q000139:chemically induced; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D017290:Menogaril / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009503:Neutropenia / Q000139:chemically induced; D012042:Registries; D014571:Urologic Neoplasms / Q000188:drug therapy*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced
chemical_list: D000903:Antibiotics, Antineoplastic; D017290:Menogaril